A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates

FASEB Journal

Volumn 26, Issue 5, 2012, Pages 2154-2163

  Johnston, Tom H ^a   Millar, Zak ^c   Huot, Philippe ^a   Wagg, Keith ^e   Thiele, Sherri ^f   Salomonczyk, Danielle ^f   Yong Kee, Christopher J ^f   Gandy, Michael N ^d   McIldowie, Matthew ^d   Lewis, Katie D ^d   Gomez Ramirez, Jordi ^a   Lee, Joohyung ^a   Fox, Susan H ^b   Martin Iverson, Mathew ^c   Nash, Joanne E ^f   Piggott, Matthew J ^d   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Drug of abuse; Ecstasy; Methylenedioxymethamphetamine; Translational medicine

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 (BENZO[D][1,3]DIOXOL 5 YL) 1 CYCLOPROPYL N METHYLETHANAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; CITALOPRAM; DOPAMINE; DOPAMINE TRANSPORTER; ILLICIT DRUG; KETANSERIN; LEVODOPA; MAPROTILINE; MESULERGINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 3 METHYL 4 (4 PYRIDYL)BENZAMIDE; NISOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; PAROXETINE; RADIOLIGAND; RESERPINE; SEROTONIN; SEROTONIN 2A RECEPTOR; SPIPERONE; TRITIUM; UNCLASSIFIED DRUG; UWA 101; VANOXERINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BRAIN SYNAPTOSOME; CALLITRICHINAE; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSKINESIA; FOOD INTAKE; HUMAN; HUMAN CELL; LOCOMOTION; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; STRUCTURE ACTIVITY RELATION; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIPARKINSON AGENTS; CELL LINE, TUMOR; DRUG SYNERGISM; LEVODOPA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; PARKINSONIA; PRIMATES;

EID: 84860913121     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.11-195016     Document Type: Article

References (32)

1. Poewe, W. (2009) Treatments for Parkinson disease-past achievements and current clinical needs. Neurology 72, S65-73
2. Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., and Goetz, C. G. (2007) Levodopa-induced dyskinesias. Mov. Disord. 22, 1379-1389; quiz 1523
3. Iravani, M. M., Jackson, M. J., Kuoppamaki, M., Smith, L. A., and Jenner, P. (2003) 3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated primates. J. Neurosci. 23, 9107-9115 (Pubitemid 37243811)
4. Bishop, C., Taylor, J. L., Kuhn, D. M., Eskow, K. L., Park, J. Y., and Walker, P. D. (2006) MDMA and fenfluramine reduce l-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci. 23, 2669-2676 (Pubitemid 43801458)
5. Huot, P. H., Johnston, T. H., Lewis, K. D., Koprich, J. B., Reyes, G., Fox, S. H., Piggott, M. J., and Brotchie, J. M. (2011) Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J. Neurosci. 31, 7190-7198
6. Green, A. R., Mechan, A. O., Elliott, J. M., O'Shea, E., and Colado, M. I. (2003) The pharmacology and clinical pharmacology of 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55, 463-508 (Pubitemid 37013213)
7. Ricaurte, G. A., McCann, U. D., Szabo, Z., and Scheffel, U. (2000) Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Toxicol. Lett. 112-113, 143-146 (Pubitemid 30138115)
8. Gandy, M. N., McIldowie, M. J., Lewis, K., Wasik, A. M., Salomonczyk, D., Wagg, K., Millar, Z. A., Tindiglia, D., Huot, P., Johnston, T. H., Thiele, S., Nguyen, B., Barnes, N. M., Brotchie, J. M., Martin-Iverson, M. T., Nash, J. E., Gordon, J., and Piggott, M. J. (2010) Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity. Med. Chem. Comm. 1, 287-293
9. Wasik, A. M., Gandy, M. N., McIldowie, M., Holder, M. J., Chamba, A., Challa, A., Lewis, K. D., Young, S. P., Scheel- Toellner, D., Dyer, M. J., Barnes, N. M., Piggott, M. J., and Gordon, J. (2011) Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ("ecstasy") through iterative chemical redesign: mechanisms and pathways to cell death. [E-pub ahead of print] Invest. New Drugs doi: 10.1007/s10637-011-9730-5
10. Bernschneider-Reif, S., Oxler, F., and Freudenmann, R. W. (2006) The origin of MDMA ("ecstasy")-separating the facts from the myth. Pharmazie 61, 966-972 (Pubitemid 44807273)
11. Shulgin, A. T., Shulgin, A., and Nichols, D. E. (1991) Phenethylamines I Have Known and Loved: A Chemical Love Story. Transform Press, Berkeley, CA, USA
12. Yoneda, F., Moto, T., Sakae, M., Ohde, H., Knoll, B., Miklya, I., and Knoll, J. (2001) Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2- propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorg. Med. Chem. 9, 1197-1212 (Pubitemid 32453280)
13. Johnston, T. H., Lee, J., Gomez-Ramirez, J., Fox, S. H., and Brotchie, J. M. (2005) A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Exp. Neurol. 191, 243-250 (Pubitemid 40092867)
14. Visanji, N. P., Fox, S. H., Johnston, T., Reyes, G., Millan, M. J., and Brotchie, J. M. (2009) Dopamine D3 receptor stimulation underlies the development of l-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol. Dis. 35, 184-192
15. Hoffman, H. S., and Ison, J. R. (1980) Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol. Rev. 87, 175-189
16. Hince, D. A., and Martin-Iverson, M. T. (2005) Differences in prepulse inhibition (PPI) between Wistar and Sprague-Dawley rats clarified by a new method of PPI standardization. Behav. Neurosci. 119, 66-77 (Pubitemid 40279498)
17. Colombo, G., Agabio, R., Balaklievskaia, N., Lobina, C., Reali, R., Fadda, F., and Gessa, G. L. (1996) T-maze and food reinforcement: an inexpensive drug discrimination procedure. J. Neurosci. Methods 67, 83-87 (Pubitemid 26268300)
18. Cheng, Y., and Prusoff, W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108
19. Boyer, E. W., and Shannon, M. (2005) The serotonin syndrome. N. Engl. J. Med. 352, 1112-1120
20. Ricaurte, G. A., Forno, L. S., Wilson, M. A., DeLanney, L. E., Irwin, I., Molliver, M. E., and Langston, J. W. (1988) (+/-)3,4-Methylene- dioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260, 51-55
21. Baumann, M. H., Wang, X., and Rothman, R. B. (2007) 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl.) 189, 407-424 (Pubitemid 44791212)
22. Corrigall, W. A., Robertson, J. M., Coen, K. M., and Lodge, B. A. (1992) The reinforcing and discriminative stimulus properties of para-ethoxy- and para-methoxyamphetamine. Pharmacol. Biochem. Behav. 41, 165-169
23. Kehne, J. H., McCloskey, T. C., Taylor, V. L., Black, C. K., Fadayel, G. M., and Schmidt, C. J. (1992) Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats. J. Pharmacol. Exp. Ther. 260, 78-89
24. Conductier, G., Crosson, C., Hen, R., Bockaert, J., and Compan, V. (2005) 3,4-N-methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS102221. Neuropsychopharmacology 30, 1056-1063 (Pubitemid 40720963)
25. Battaglia, G., Brooks, B. P., Kulsakdinun, C., and De Souza, E. B. (1988) Pharmacologic profile of MDMA (3,4-methylenedioxy-methamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 149, 159-163
26. Verrico, C. D., Miller, G. M., and Madras, B. K. (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl.) 189, 489-503 (Pubitemid 44791219)
27. Hansard, M. J., Smith, L. A., Jackson, M. J., Cheetham, S. C., and Jenner, P. (2002) Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4- phenyl-1,2,3,6- tetrahydropyridine-treated primates. J. Pharmacol. Exp. Ther. 303, 952-958 (Pubitemid 35424376)
28. Carta, M., Carlsson, T., Kirik, D., and Bjorklund, A. (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833 (Pubitemid 47343795)
29. Munoz, A., Li, Q., Gardoni, F., Marcello, E., Qin, C., Carlsson, T., Kirik, D., Di Luca, M., Bjorklund, A., Bezard, E., and Carta, M. (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 131, 3380-3394
30. Lane, E. L., Cheetham, S., and Jenner, P. (2005) Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J. Pharmacol. Exp. Ther. 312, 1124-1131 (Pubitemid 40293772)
31. Capela, J. P., Fernandes, E., Remiao, F., Bastos, M. L., Meisel, A., and Carvalho, F. (2007) Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. Neurotoxicology 28, 868-875 (Pubitemid 47064474)
32. Liechti, M. E., Saur, M. R., Gamma, A., Hell, D., and Vollenweider, F. X. (2000) Psychological and physiological effects of MDMA ("ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23, 396-404